 3. Any number of prior therapies including none. For subjects who have received prior systemic treatment with cytotoxic T-lymphocyte-associated protein 4 CTLA-4, Programmed death 1 PD-1 andor Programmed death-ligand 1 PD-L1 therapy, the last monoclonal antibody administration should be no less than 6 weeks prior to start of this protocol therapy and all prior side effects must have resolved to grade 1 or less by the time of the start of this protocol therapy. 